<ul>
<li>2 個理由説明 Absci 可能是 AI 生物科技的未來，以及 1 個風險</li>
</ul>
<p>Absci Corporation（NASDAQ:ABSI - 免費報告）- HC Wainwright 的股票研究人員在 5 月 11 日星期一發布的研究報告中提高了對 Absci 2026 年第三季度每股收益的預期。HC Wainwright 分析師 S. Ramakanth 現在預計該公司本季度每股收益為（$0.22），高於之前預測的（$0.23）。市場普遍預計 Absci 當前全年的每股收益為（$0.83）。HC Wainwright 還對 Absci 2026 年第四季度的收益進行了預測，預計為每股（$0.22），2026 財年的收益為每股（$0.84），2027 年第一季度的收益為每股（$0.12），2027 年第二季度的收益為每股（$0.16），2027 年第三季度的收益為每股$0.12，2027 年第四季度的收益為每股（$0.18），2028 財年的收益為每股$0.11，以及 2029 財年的收益為每股$0.09。</p>
<p>Absci（NASDAQ:ABSI - 獲取免費報告）在 5 月 7 日星期四發佈了其收益結果。該公司報告本季度每股收益為（$0.19），超出分析師普遍預期的（$0.20）$0.01。Absci 的淨利潤率為負的 6450.76%，股本回報率為負的 66.32%。該公司在本季度的收入為 22 萬美元，而市場普遍預期為 139 萬美元。</p>
<ul>
<li>現在哪個醫療保健股票是最佳買入？</li>
</ul>
<p>其他幾家研究公司最近也對 ABSI 發表了評論。Truist Financial 在 5 月 8 日星期五的報告中將 Absci 的目標價從$9.00 上調至$11.00，並給予該股票 “買入” 評級。Weiss Ratings 在 4 月 20 日星期一的報告中重申了對 Absci 的 “賣出（d-）” 評級。最後，Needham &amp; Company LLC 在 3 月 25 日星期三的報告中重申了 “買入” 評級，並對 Absci 的目標價設定為$7.00。四位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為$7.58。</p>
<p><strong>閲讀我們關於 Absci 的最新報告</strong></p>
<h2>Absci 股票下跌 7.3%</h2>
<p>Absci 股票在星期三開盤價為$5.36。Absci 的 12 個月低點為$2.24，12 個月高點為$6.72。該公司的 50 日移動平均價格為$3.47，200 日移動平均價格為$3.34。該公司的市值為 8.3565 億美元，市盈率為-6.46，貝塔值為 2.36。</p>
<h2>Absci 的機構交易</h2>
<p>幾家機構投資者和對沖基金最近對 ABSI 的持倉進行了調整。AQR Capital Management LLC 在第一季度將其在 Absci 的持倉提高了 279.4%。AQR Capital Management LLC 現在擁有 55,538 股該公司的股票，價值 139,000 美元，此前在上個季度購買了 40,901 股。高盛集團在第一季度將其在 Absci 的持倉提高了 17.5%。高盛集團現在擁有 314,858 股該公司的股票，價值 790,000 美元，此前在上個季度購買了 46,975 股。Woodline Partners LP 在第一季度將其在 Absci 的持倉提高了 32.9%。Woodline Partners LP 現在擁有 1,391,245 股該公司的股票，價值 3,492,000 美元，此前在上個季度購買了 344,270 股。Geode Capital Management LLC 在第二季度將其在 Absci 的持倉提高了 22.5%。Geode Capital Management LLC 現在擁有 2,445,450 股該公司的股票，價值 6,286,000 美元，此前在上個季度購買了 448,984 股。最後，Creative Planning 在第二季度將其在 Absci 的持倉提高了 145.4%。Creative Planning 現在擁有 46,882 股該公司的股票，價值 120,000 美元，此前在上個季度購買了 27,775 股。對沖基金和其他機構投資者持有該公司 52.05% 的股票。</p>
<h2>Absci 的內部交易</h2>
<p>在其他新聞中，內部人士 Andreas Busch 在 3 月 12 日星期四以每股平均成本$2.29 購買了 100,000 股該股票，總交易額為$229,000.00。購買後，該內部人士直接持有 421,446 股該公司的股票，價值$965,111.34。此交易代表其持倉增加了 31.11%。該交易已在向證券交易委員會提交的文件中披露，文件可通過 SEC 網站獲取。10.49% 的股票由公司內部人士持有。</p>
<h2>Absci 新聞匯總</h2>
<p>以下是本週影響 Absci 的主要新聞：</p>
<ul>
<li>積極情緒：HC Wainwright 提高了對 Absci 的長期收益展望，包括對 2028 財年和 2029 財年每股收益的上調，暗示盈利前景隨着時間的推移而改善。Absci 分析師估計更新</li>
<li>積極情緒：該公司還上調了對 2030 財年每股收益的預期，強化了 Absci 如果執行改善可能在未來幾年產生可觀收益的觀點。Absci 分析師估計更新</li>
<li>中性情緒：HC Wainwright 對近期的估計進行了適度修訂，包括對 2026 年第三季度和第四季度每股收益的略微上調，但預計該公司在至少 2027 年之前仍將出現虧損。Absci 分析師估計更新</li>
<li>消極情緒：即使在修訂後的估計中，市場共識預期仍指向全年虧損，而 Absci 最近的季度結果顯示收入遠低於預期，給股票帶來壓力。Absci 收益結果</li>
</ul>
<h2>Absci 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Absci Corporation NASDAQ: ABSI 是一家生物技術公司，利用機器學習、合成生物學和自動化技術加速基於蛋白質的治療藥物的發現和開發。該公司的綜合藥物創制平台（Integrated Drug Creation®，IDC®）旨在以傳統生物製藥發現方法無法匹敵的速度和規模識別和生產新型抗體和酶候選物。Absci 與製藥和生物技術合作伙伴合作，生成、篩選和優化用於廣泛治療應用的蛋白質分子。</p>
<p>Absci 的核心產品是其端到端的發現引擎，該引擎結合了專有算法、高通量實驗室自動化和深度學習框架。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，優於 Absci</li>
<li>Ally Financial 迴歸基礎，投資者在關注</li>
<li>Navitas 因印度交易突破，驗證高功率 AI 轉型</li>
<li>海軍催化劑點燃 Odysight 的增長引擎</li>
<li>AST SpaceMobile 因銀河第一季度業績不佳暴跌：垂直整合能拯救 SpaceX 競爭對手嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJTSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJTSQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Absci 嗎？</h2>
<p>在考慮 Absci 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Absci 並不在名單上。</p>
<p>雖然 Absci 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ABSI

<p>HC Wainwright 將 Absci Corporation (NASDAQ:ABSI) 2026 年第三季度每股收益（EPS）預估從（$0.23）上調至（$0.22）。全年共識預估為每股（$0.83）。Absci 在第一季度報告的每股收益為（$0.19），超出預期。分析師對該股票的評級不一，整體評級為 “適度買入”，目標價為 $7.58。Absci 的股票目前下跌 7.3%，交易價格為 $5.36，市值為 $8.3565 億。內部人士 Andreas Busch 最近將其持股增加了 31.11%</p>

<ul>
<li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>2 個理由説明 Absci 可能是 AI 生物科技的未來，以及 1 個風險</li>
</ul>
</div><p>Absci Corporation (NASDAQ:ABSI - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Absci in a research report issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.22) per share for the quarter, up from their prior forecast of ($0.23). The consensus estimate for Absci's current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Absci's Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at $0.12 EPS, Q4 2027 earnings at ($0.18) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.09 EPS.</p>
<div class="lb-trans"><p>Absci Corporation（NASDAQ:ABSI - 免費報告）- HC Wainwright 的股票研究人員在 5 月 11 日星期一發布的研究報告中提高了對 Absci 2026 年第三季度每股收益的預期。HC Wainwright 分析師 S. Ramakanth 現在預計該公司本季度每股收益為（$0.22），高於之前預測的（$0.23）。市場普遍預計 Absci 當前全年的每股收益為（$0.83）。HC Wainwright 還對 Absci 2026 年第四季度的收益進行了預測，預計為每股（$0.22），2026 財年的收益為每股（$0.84），2027 年第一季度的收益為每股（$0.12），2027 年第二季度的收益為每股（$0.16），2027 年第三季度的收益為每股$0.12，2027 年第四季度的收益為每股（$0.18），2028 財年的收益為每股$0.11，以及 2029 財年的收益為每股$0.09。</p>
</div><p>Absci (NASDAQ:ABSI - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.01. Absci had a negative net margin of 6,450.76% and a negative return on equity of 66.32%. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $1.39 million.</p>
<div class="lb-trans"><p>Absci（NASDAQ:ABSI - 獲取免費報告）在 5 月 7 日星期四發佈了其收益結果。該公司報告本季度每股收益為（$0.19），超出分析師普遍預期的（$0.20）$0.01。Absci 的淨利潤率為負的 6450.76%，股本回報率為負的 66.32%。該公司在本季度的收入為 22 萬美元，而市場普遍預期為 139 萬美元。</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在哪個醫療保健股票是最佳買入？</li>
</ul>
</div><p>Several other research firms also recently commented on ABSI. Truist Financial raised their price objective on shares of Absci from $9.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, May 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Absci in a report on Monday, April 20th. Finally, Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $7.00 price objective on shares of Absci in a report on Wednesday, March 25th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.58.</p>
<div class="lb-trans"><p>其他幾家研究公司最近也對 ABSI 發表了評論。Truist Financial 在 5 月 8 日星期五的報告中將 Absci 的目標價從$9.00 上調至$11.00，並給予該股票 “買入” 評級。Weiss Ratings 在 4 月 20 日星期一的報告中重申了對 Absci 的 “賣出（d-）” 評級。最後，Needham &amp; Company LLC 在 3 月 25 日星期三的報告中重申了 “買入” 評級，並對 Absci 的目標價設定為$7.00。四位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為$7.58。</p>
</div><p><strong>Read Our Latest Report on Absci</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Absci 的最新報告</strong></p>
</div><h2>Absci Stock Down 7.3%</h2>
<div class="lb-trans"><h2>Absci 股票下跌 7.3%</h2>
</div><p>Absci stock opened at $5.36 on Wednesday. Absci has a twelve month low of $2.24 and a twelve month high of $6.72. The firm has a 50 day moving average price of $3.47 and a 200-day moving average price of $3.34. The company has a market capitalization of $835.65 million, a P/E ratio of -6.46 and a beta of 2.36.</p>
<div class="lb-trans"><p>Absci 股票在星期三開盤價為$5.36。Absci 的 12 個月低點為$2.24，12 個月高點為$6.72。該公司的 50 日移動平均價格為$3.47，200 日移動平均價格為$3.34。該公司的市值為 8.3565 億美元，市盈率為-6.46，貝塔值為 2.36。</p>
</div><h2>Institutional Trading of Absci</h2>
<div class="lb-trans"><h2>Absci 的機構交易</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in ABSI. AQR Capital Management LLC raised its position in shares of Absci by 279.4% during the 1st quarter. AQR Capital Management LLC now owns 55,538 shares of the company's stock valued at $139,000 after buying an additional 40,901 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Absci by 17.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 314,858 shares of the company's stock valued at $790,000 after buying an additional 46,975 shares in the last quarter. Woodline Partners LP raised its position in shares of Absci by 32.9% during the 1st quarter. Woodline Partners LP now owns 1,391,245 shares of the company's stock valued at $3,492,000 after buying an additional 344,270 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Absci by 22.5% during the 2nd quarter. Geode Capital Management LLC now owns 2,445,450 shares of the company's stock valued at $6,286,000 after buying an additional 448,984 shares in the last quarter. Finally, Creative Planning raised its position in shares of Absci by 145.4% during the 2nd quarter. Creative Planning now owns 46,882 shares of the company's stock valued at $120,000 after buying an additional 27,775 shares in the last quarter. Hedge funds and other institutional investors own 52.05% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近對 ABSI 的持倉進行了調整。AQR Capital Management LLC 在第一季度將其在 Absci 的持倉提高了 279.4%。AQR Capital Management LLC 現在擁有 55,538 股該公司的股票，價值 139,000 美元，此前在上個季度購買了 40,901 股。高盛集團在第一季度將其在 Absci 的持倉提高了 17.5%。高盛集團現在擁有 314,858 股該公司的股票，價值 790,000 美元，此前在上個季度購買了 46,975 股。Woodline Partners LP 在第一季度將其在 Absci 的持倉提高了 32.9%。Woodline Partners LP 現在擁有 1,391,245 股該公司的股票，價值 3,492,000 美元，此前在上個季度購買了 344,270 股。Geode Capital Management LLC 在第二季度將其在 Absci 的持倉提高了 22.5%。Geode Capital Management LLC 現在擁有 2,445,450 股該公司的股票，價值 6,286,000 美元，此前在上個季度購買了 448,984 股。最後，Creative Planning 在第二季度將其在 Absci 的持倉提高了 145.4%。Creative Planning 現在擁有 46,882 股該公司的股票，價值 120,000 美元，此前在上個季度購買了 27,775 股。對沖基金和其他機構投資者持有該公司 52.05% 的股票。</p>
</div><h2>Insider Transactions at Absci</h2>
<div class="lb-trans"><h2>Absci 的內部交易</h2>
</div><p>In other news, insider Andreas Busch bought 100,000 shares of the stock in a transaction on Thursday, March 12th. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $229,000.00. Following the purchase, the insider directly owned 421,446 shares of the company's stock, valued at $965,111.34. This trade represents a 31.11% increase in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. 10.49% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Andreas Busch 在 3 月 12 日星期四以每股平均成本$2.29 購買了 100,000 股該股票，總交易額為$229,000.00。購買後，該內部人士直接持有 421,446 股該公司的股票，價值$965,111.34。此交易代表其持倉增加了 31.11%。該交易已在向證券交易委員會提交的文件中披露，文件可通過 SEC 網站獲取。10.49% 的股票由公司內部人士持有。</p>
</div><h2>Absci News Roundup</h2>
<div class="lb-trans"><h2>Absci 新聞匯總</h2>
</div><p>Here are the key news stories impacting Absci this week:</p>
<div class="lb-trans"><p>以下是本週影響 Absci 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright raised its longer-term earnings outlook for Absci, including higher FY2028 and FY2029 EPS estimates, suggesting improving profitability prospects over time. Absci analyst estimate updates</li>
<li>Positive Sentiment: The firm also nudged up its FY2030 EPS estimate, reinforcing the view that Absci could generate meaningful earnings in the out-years if execution improves. Absci analyst estimate updates</li>
<li>Neutral Sentiment: HC Wainwright also made modest revisions to near-term estimates, including slightly better Q3 2026 and Q4 2026 EPS forecasts, but the company is still expected to post losses through at least 2027. Absci analyst estimate updates</li>
<li>Negative Sentiment: Even with the revised estimates, consensus expectations still point to a full-year loss, and Absci’s recent quarterly results showed very low revenue versus expectations, keeping pressure on the stock. Absci earnings results</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：HC Wainwright 提高了對 Absci 的長期收益展望，包括對 2028 財年和 2029 財年每股收益的上調，暗示盈利前景隨着時間的推移而改善。Absci 分析師估計更新</li>
<li>積極情緒：該公司還上調了對 2030 財年每股收益的預期，強化了 Absci 如果執行改善可能在未來幾年產生可觀收益的觀點。Absci 分析師估計更新</li>
<li>中性情緒：HC Wainwright 對近期的估計進行了適度修訂，包括對 2026 年第三季度和第四季度每股收益的略微上調，但預計該公司在至少 2027 年之前仍將出現虧損。Absci 分析師估計更新</li>
<li>消極情緒：即使在修訂後的估計中，市場共識預期仍指向全年虧損，而 Absci 最近的季度結果顯示收入遠低於預期，給股票帶來壓力。Absci 收益結果</li>
</ul>
</div><h2>Absci Company Profile</h2>
<div class="lb-trans"><h2>Absci 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Absci Corporation NASDAQ: ABSI is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company's Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.</p>
<div class="lb-trans"><p>Absci Corporation NASDAQ: ABSI 是一家生物技術公司，利用機器學習、合成生物學和自動化技術加速基於蛋白質的治療藥物的發現和開發。該公司的綜合藥物創制平台（Integrated Drug Creation®，IDC®）旨在以傳統生物製藥發現方法無法匹敵的速度和規模識別和生產新型抗體和酶候選物。Absci 與製藥和生物技術合作伙伴合作，生成、篩選和優化用於廣泛治療應用的蛋白質分子。</p>
</div><p>The core of Absci's offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.</p>
<div class="lb-trans"><p>Absci 的核心產品是其端到端的發現引擎，該引擎結合了專有算法、高通量實驗室自動化和深度學習框架。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Absci</li>
<li>Ally Financial Is Back to Basics—And Investors Are Watching</li>
<li>Navitas Breaks Out on India Deal, Validating High-Power AI Pivot</li>
<li>Navy Catalyst Ignites Odysight’s Growth Engine</li>
<li>AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，優於 Absci</li>
<li>Ally Financial 迴歸基礎，投資者在關注</li>
<li>Navitas 因印度交易突破，驗證高功率 AI 轉型</li>
<li>海軍催化劑點燃 Odysight 的增長引擎</li>
<li>AST SpaceMobile 因銀河第一季度業績不佳暴跌：垂直整合能拯救 SpaceX 競爭對手嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJTSQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ABSI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Absci Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Absci 嗎？</h2>
</div><p>Before you consider Absci, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Absci 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Absci 並不在名單上。</p>
</div><p>While Absci currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Absci 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 對 Absci 第三季度的收益預期持樂觀態度